Piramal Healthcare UK Ltd. has invested £2.0 million to expand its manufacturing base at Grangemouth, Scotland, to manufacture Antibody Drug Conjugates for global markets. The new facility will add approximately 20 high-skill jobs and the company expects the investment will yield additional revenue of £3-5 million over a period of five years.
 
Scotland has become a globally competitive base for sustainable high-value manufacturing. Scotland’s globally competitive Pharma services sector includes more than 160 companies, a quality controlled environment, supportive clinical trial environment and high quality manufacture.
  
Piramal Healthcare site lead, Mark Wright, said, “Piramal has been growing its operations in Grangemouth since 2005 and currently employs around 140 people in predominantly highly skilled positions. We aim to scale up this facility in the next five years to maintain its position as a global leader in the production of Antibody Drug Conjugates.”